DAWN Q3 2021 Earnings — Day One Biopharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

DAWNDay One Biopharmaceuticals, Inc.

$2B

Q3 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

-$50,000

Operating Income

-$19M

Net Income

-$19M

EPS (Diluted)

$-0.31

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$12M

Free Cash Flow

-$12M

Stock-Based Comp.

$5M

Balance Sheet

Total Assets

$304M

Total Liabilities

$6M

Stockholders' Equity

$298M

Cash & Equivalents

$297M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	-$50,000	-$46,000	-8.7%
Operating Income	-$19M	-$4M	-440.3%
Net Income	-$19M	-$3M	-581.3%